Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes and chronic kidney disease in primary and secondary cardiovascular prevention groups: Results from the randomized CREDENCE trial
Circulation Jul 18, 2019
Mahaffey KW, et al. - Given that canagliflozin attenuates renal failure risk in patients with type 2 diabetes and chronic kidney disease, researchers explored its impacts on specific cardiovascular outcomes as well as in those without prior cardiovascular disease (primary prevention). Participants (n=4,401) were patients with type 2 diabetes and chronic kidney disease. In a random manner, these patients received canagliflozin or placebo with optimized standard of care. Relative to secondary prevention participants (N=2,220; 50.4%), the primary prevention participants (N=2181; 49.6%) had younger age, shorter diabetes duration, and were more often female. In patients with type 2 diabetes and chronic kidney disease, including those without prior cardiovascular disease, a significant reduction in major cardiovascular events and kidney failure was evident in relation to treatment with canagliflozin.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data